HCPCS Level II code J2440 denotes the injectable administration of papaverine hydrochloride, up to 60 mg. As a drug-specific HCPCS code, J2440 provides a standardized way for providers and payers to identify and bill for this vasoactive pharmacologic agent when administered by injection. Nationally, such codes matter because they enable consistent drug identification, claims processing, and payment across a range of outpatient and facility settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing and coding context for J2440, typical sites of service where the drug is administered, and the common modifiers used with HCPCS Level II drug codes. The publication also outlines benchmarks and policy considerations relevant to drug-specific HCPCS coding, including payer coverage patterns and billing practice nuances.

This summary equips revenue cycle stakeholders, clinical coders, and policy analysts with the clinical context and coding basics for HCPCS Level II code J2440, clarifying where it is used and what aspects of billing and policy to examine further.